CEO says repurchase program designed to improve shareholder value

LAFAYETTE, Louisiana—Viemed Healthcare, Inc., a provider of in-home, technology-enabled post-acute respiratory care, announced that its board of directors has authorized a share repurchase program, effective through June 2026.

Under the share repurchase program, Viemed may purchase up to 1,976,441 common shares of the company from time to time in accordance with applicable securities laws, representing approximately 5% of the total issued and outstanding common shares as of March 31, 2025.

The company intends to repurchase common shares through open market purchases, block purchases or otherwise in accordance with applicable securities laws. Subject to certain exceptions for block purchases, daily purchases will be limited to 25% of the average daily volume for the four calendar weeks preceding the date of purchase.

“Our recent first quarter 2025 results and the increases in our 2025 guidance range midpoints demonstrate that we are executing well with strong underlying fundamentals in the business," said Casey Hoyt, Viemed's CEO. "We have a track record of disciplined capital allocation, with our latest example being the attractive acquisition of Lehan’s Medical that is expected to close in the third quarter of this year.

"Since our public listing, we have repurchased approximately 2.6 million shares, underscoring our commitment to executing on our capital allocation strategies," Hoyt continued. "With no net debt and full availability on our $55 million credit facility, we have ample liquidity to improve shareholder value with a new share repurchase program while also funding our organic and inorganic growth initiatives.”


The price paid for the common shares will be the market price at the time of purchase, plus applicable brokerage fees or such other prices as may be permitted by applicable securities laws. There can be no assurance as to the precise number of common shares that will be repurchased under the program, if any. The company may discontinue its purchases at any time, subject to compliance with applicable securities laws. The common shares purchased by the company will be canceled.